US 12,305,238 B2
Methods for treatment of thyroid cancer
Giulia C. Kennedy, San Francisco, CA (US); Darya I. Chudova, San Jose, CA (US); Eric T. Wang, Milpitas, CA (US); Jonathan I. Wilde, Burlingame, CA (US); Bonnie H. Anderson, Half Moon Bay, CA (US); Hui Wang, San Bruno, CA (US); Moraima Pagan, San Francisco, CA (US); and Nusrat Rabbee, South San Francisco, CA (US)
Assigned to Veracyte, Inc., South San Francisco, CA (US)
Filed by Veracyte, Inc., South San Francisco, CA (US)
Filed on Sep. 23, 2024, as Appl. No. 18/893,597.
Application 18/893,597 is a continuation of application No. 16/781,891, filed on Feb. 4, 2020.
Application 16/781,891 is a continuation of application No. 16/353,248, filed on Mar. 14, 2019, granted, now 10,672,504, issued on Jun. 2, 2020.
Application 16/353,248 is a continuation of application No. 15/661,496, filed on Jul. 27, 2017, granted, now 10,236,078, issued on Mar. 19, 2019.
Application 15/661,496 is a continuation in part of application No. 15/274,492, filed on Sep. 23, 2016, granted, now 9,856,537, issued on Jan. 2, 2018.
Application 15/661,496 is a continuation in part of application No. 13/589,022, filed on Aug. 17, 2012, abandoned.
Application 15/274,492 is a continuation of application No. 12/964,666, filed on Dec. 9, 2010, granted, now 9,495,515, issued on Nov. 15, 2016.
Application 13/589,022 is a continuation of application No. 12/592,065, filed on Nov. 17, 2009, granted, now 8,541,170, issued on Sep. 24, 2013.
Claims priority of provisional application 61/285,165, filed on Dec. 9, 2009.
Claims priority of provisional application 61/270,812, filed on Jul. 13, 2009.
Claims priority of provisional application 61/199,585, filed on Nov. 17, 2008.
Prior Publication US 2025/0034646 A1, Jan. 30, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01); C12Q 1/6886 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 1/6886 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01)] 28 Claims
 
1. A method for treating thyroid cancer of a subject, comprising:
(a) obtaining a fine needle aspiration (FNA) sample of thyroid tissue of said subject, wherein said subject has or is suspected of having thyroid cancer, and wherein said FNA sample of thyroid tissue comprises messenger ribonucleic acid (mRNA);
(b) subjecting a first portion of said FNA sample of thyroid tissue to cytological testing that indicates that said first portion of said FNA sample of thyroid tissue is indeterminate;
(c) upon identifying said first portion of said FNA sample of thyroid tissue as indeterminate, sequencing nucleic acid molecules obtained or derived from mRNA of a second portion of said FNA sample of thyroid tissue, to yield a set of mRNA levels in said second portion of said FNA sample,
wherein said set of mRNA levels corresponds to at least two genes selected from the group consisting of: ALK, CALCA, DICER1, IGF2BP3, MET, NTRK1, NTRK3, PAX8, KPNA2, SMARCA5, and THADA;
(d) computer processing said set of mRNA levels from (c) to generate a classification of said FNA sample of thyroid tissue as positive for said thyroid cancer; and
(e) responsive to generating said classification of said FNA sample of thyroid tissue as positive for said thyroid cancer, administering a treatment to said subject, thereby treating said thyroid cancer of said subject, wherein said treatment comprises a thyroidectomy, a lobectomy, or radioactive iodine ablation.